Daniel Connolly Memphis Commercial Appeal Published 10:06 AM EDT Oct 19, 2018 Gabby Salinas came to St. Jude Children's Research Hospital from Bolivia at age 7 as a cancer patient. Then a highway crash killed her father and younger sister, and paralyzed her mother. The tragic circumstances made national news. Today, at age 30, Salinas is in the news for another reason. She made her first run for office earlier this year, defeating two opponents to become the Democratic nominee for a Memphis-area state Senate seat. Now she seeks to defeat the Republican incumbent, Brian Kelsey. And a Republican group is spending more than $300,000 on advertising to stop her. "It's a lot of money," said John Geer, a political science professor at Vanderbilt University. "That tells me they are worried about this challenger." State legislative seats frequently aren't contested at all, and it's uncommon to see so much money pouring into a race in which the … [Read more...] about Gabby Salinas aims to unseat Brian Kelsey in Tennessee state Senate race
Ordinary income tax rate vs capital gains
Significant progress with RPL554 as potential treatment for COPD and CF Recently initiated important Phase 2 trial as add-on to dual bronchodilator therapy for COPD maintenance treatment LONDON, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today an operational update and financial results for the three months and six months ended June 30, 2018. The Company’s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4, or PDE3 and PDE4, that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (“COPD”) and cystic fibrosis (“CF”), and … [Read more...] about Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2018
MANCHESTER, Conn., July 31, 2018 (GLOBE NEWSWIRE) -- LYDALL, INC. (NYSE: LDL) today announced financial results for the second quarter ended June 30, 2018. HIGHLIGHTS - Q2 2018 vs. Q2 2017 GAAP Financials /EIN News/ -- • Net sales of $186.4 million, up $11.5 million, or 6.6% Non-GAAP Financial Measures* • Organic sales growth of 2.3% *Reconciliations of the Non-GAAP financial measures to Lydall’s GAAP financial results are included at the end of this release. See also “Use of Non-GAAP Financial Measures” below. Dale G. Barnhart, President and Chief Executive Officer, stated, “Sales increased 6.6%, with organic sales growth of 2.3%, led by the Performance Materials and Technical Nonwovens segments. Our results reflect the negative impact of approximately $2.2 million from a supplier fire which forced temporary shutdowns of certain Thermal … [Read more...] about Lydall Announces Financial Results for the Second Quarter Ended June 30, 2018
LONDON, July 27, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) (Nasdaq:HCM) today announces its unaudited financial results for the six months ended June 30, 2018 and updates shareholders on key clinical programs. Fruquintinib made substantial progress through China New Drug Application (“NDA”) process, aiming for approval and launch for colorectal cancer (“CRC”) this year; we also target to report Phase III top-line results for non-small cell lung cancer (“NSCLC”) in Q4 2018; Savolitinib has two registration studies underway, global Phase III in papillary renal cell carcinoma (“PRCC”) and China registration intent Phase II in MET exon 14 mutation/deletion NSCLC; also Tagrisso®/savolitinib combination studies in NSCLC indications are in planning, and set to start in late 2018 and early 2019; Expansion of U.S. and international operations firmly underway, … [Read more...] about Chi-Med Reports 2018 Interim Results and Updates Shareholders on Key Clinical Programs
With Breanne Deppisch and Joanie Greve. THE BIG IDEA: Neither President Trump nor his lawyer wants to talk under oath. -- Michael Cohen — Trump’s longtime attorney and consigliere — told a federal judge in California last night that he will invoke his Fifth Amendment right not to incriminate himself in a civil case brought by adult entertainer Stormy Daniels. He made the declaration as part of a request to pause that lawsuit, citing an “ongoing criminal investigation by the FBI and U.S. Attorney for the Southern District of New York.” -- Separately, Rudy Giuliani — who joined Trump’s legal team last week — met with special counsel Robert Mueller to reopen negotiations for a presidential interview. The former New York mayor, who has known Mueller for decades, “conveyed the ongoing resistance of Trump and his advisers to an interview with federal investigators, but did not rule out the possibility,” Robert Costa and Carol … [Read more...] about The Daily 202: Michael Cohen will take the Fifth. Trump has said innocent people don’t do that.